Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...

Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...

Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...